Table 2.
Overview of Antibiotic Therapy on Day 1 in the Preprescription Authorization and the Postprescription Review With Feedback Groups
| Therapy | Preprescription (n = 778) | Postprescription (n = 730) | P Value |
|---|---|---|---|
| Antibiotic regimen inappropriatea | 262 (33.7) | 300 (41.1) | <.01 |
| Antibiotic therapy not indicated | 138 (17.7) | 161 (22.1) | .04 |
| No bacterial infection | 122 (15.7) | 141 (19.3) | .07 |
| Treatment course completed | 9 (1.2) | 11 (1.5) | .65 |
| Prophylaxis not indicated | 7 (0.9) | 9 (1.2) | .62 |
| Antibiotic therapy too broad | 113 (14.5) | 131 (17.9) | .08 |
| Unnecessary redundant coverage | 13 (1.7) | 16 (2.2) | .57 |
| Unnecessary MRSA coverage | 39 (5.0) | 36 (4.9) | 1.00 |
| Unnecessary broad-spectrum, gram-negative coverage |
33 (4.2) | 49 (6.7) | .04 |
| Unnecessary gram-negative coverage | 14 (1.8) | 11 (1.5) | .69 |
| Unnecessary gram-positive coverage | 5 (0.6) | 3 (0.4) | .73 |
| Unnecessary anaerobic coverage | 9 (1.2) | 16 (2.2) | .16 |
| Antimicrobial therapy too narrow | 9 (1.2) | 5 (0.7) | .43 |
| Equally effective but more cost-effective options existed | 2 (0.3) | 3 (0.4) | .68 |
Data are presented as No. (%).
Abbreviation: MRSA, methicillin-resistant Staphylococcus aureus.
aFor antibiotic therapy considered inappropriate, a single reason was selected whenever possible.